

# Anebulo Pharmaceuticals Reports Fourth Quarter and Fiscal Year 2021 Financial Results and Provides a Business Update

AUSTIN, Texas--(BUSINESS WIRE)-- Anebulo Pharmaceuticals, Inc. (Nasdaq: ANEB), a clinical-stage biopharmaceutical company developing novel solutions for people suffering from acute cannabinoid intoxication and substance addiction, today announced financial results for the three and 12 months ended June 30, 2021 and reported recent business highlights.

Business highlights for the fourth quarter of fiscal year 2021 and recent weeks include the following:

- **Completed manufacturing of ANEB-001 capsules for upcoming Phase 2 clinical trial.** In compliance with current Good Manufacturing Practice requirements, the Company delivered ANEB-001's active pharmaceutical ingredient to its contract manufacturer to fill into 10 mg and 50 mg capsules for finished product.
- **Formed Scientific Advisory Board (SAB) with two founding co-chairs.** In August 2021, the Company formed the SAB to advise the Company on its clinical development programs and product pipeline. The founding co-chairs are Andrew Monte, M.D., Ph.D. and Arjun Chanmugam, M.D., both recognized leaders in emergency medicine.
- **Closed initial public offering (IPO) of common stock.** The Company completed its IPO of 3,078,224 shares of common stock at \$7.00 per share for gross proceeds to Anebulo of \$21.5 million. On May 7, 2021, the Company's common stock began trading on the Nasdaq Capital Market under the symbol ANEB.
- **Raised sufficient capital to fund operations through calendar year 2022.** Management believes the IPO net proceeds of \$19.8 million provide adequate funding for the Company's planned business operations and clinical studies through the end of calendar year 2022.
- **On track to commence Phase 2 proof-of-concept clinical trial with ANEB-001 for the treatment of acute cannabinoid intoxication in the fourth quarter of 2021.** The planned Phase 2 study will take place at a single site in the Netherlands and has been approved by the institution's regulatory and ethics committee. The study is expected to enroll 100 healthy volunteers with each to receive 10 mg of THC orally, and then randomized to one of three doses of ANEB-001 or placebo. The Company expects topline results to be available in the first half of 2022.

## Management Commentary

"We are pleased with our progress toward initiating the Phase 2 clinical study of ANEB-001

for the treatment of patients with acute cannabinoid intoxication later this year. As the number of emergency department visits related to cannabis intoxication continues to increase by approximately 15% annually, we believe there is a significant unmet medical need for our drug candidate,” stated Daniel Schneeberger, M.D., Chief Executive Officer of Anebulo. “The manufacture of finished product for ANEB-001 was a critical step in preparation for our proof-of-concept study in the Netherlands. In addition, we were delighted to announce the formation of our SAB with founding members who bring significant expertise in emergency medicine and medical toxicology. We intend to expand the SAB over time and look forward to their valuable contributions for our initial indication, as well as in the exploration of other potential indications to expand our addressable market.”

## **Financial Results**

Anebulo Pharmaceuticals commenced operations in May 2020. As such, all prior-year comparisons reflect approximately one month of operations.

- Operating expenses in the fourth quarter of fiscal 2021 were \$2,484,705 compared with \$173,351 in the same period in fiscal 2020. Operating expenses in fiscal 2021 were \$3,613,753 compared with \$173,351 in fiscal 2020.
- Net loss in the fourth quarter of fiscal 2021 was \$29,111,739, or \$(1.59) per share, compared with a net loss of \$174,637, or \$(0.01) per share, in the fourth quarter of fiscal 2020. Net loss in fiscal 2021 was \$30,252,554, or \$(2.83) per share, compared with a net loss of \$174,637, or \$(0.01) per share, in fiscal 2020. The number of shares outstanding has been adjusted to reflect the 6:1 stock split effected prior to the Company’s May 6, 2021 IPO.
- Cash was approximately \$20 million as of June 30, 2021.

## **About ANEB-001**

Anebulo believes ANEB-001 is an asset with a well-understood mechanism of action. ANEB-001 is a competitive antagonist at the human CB1 receptor with an affinity of 0.6nM with good oral bioavailability and brain penetration (brain:plasma ratio = 1.5). ANEB-001 has been shown to antagonize THC-induced hypolocomotion in mice, a CB1 receptor-mediated response.

ANEB-001 is being developed to be administered as an oral treatment, reaches potentially therapeutic blood levels within 30 minutes and is believed to rapidly reverse the signs and symptoms of cannabinoid overdose in as little as one hour. Anebulo believes there is a low likelihood of drug-drug interactions as preclinical testing demonstrated that ANEB-001 does not inhibit the metabolic cytochromes 1A2, 2C9, 2C19, 2D6 and 3A4 at pharmacologically relevant concentrations. No product is approved for acute cannabinoid intoxication and Anebulo is not aware of any competing products to reverse the symptoms of cannabinoid intoxication that are further along in the development process than ANEB-001.

## **About Anebulo Pharmaceuticals, Inc.**

Anebulo Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing novel solutions for people suffering from acute cannabinoid intoxication and substance addiction. Its lead product candidate, ANEB-001, is intended to reverse the negative effects of acute cannabinoid intoxication within one hour of administration. Clinical trials completed

to date have shown that ANEB-001 is rapidly absorbed, well tolerated and leads to weight loss, an effect that is consistent with central cannabinoid receptor type 1 antagonism. For further information about Anebulo, please visit [www.anebulo.com](http://www.anebulo.com).

## Forward-Looking Statements

This press release contains forward-looking statements as defined in Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements, along with terms such as “anticipate,” “expect,” “intend,” “may,” “will,” “should” and other comparable terms, involve risks and uncertainties because they relate to events and depend on circumstances that will occur in the future. Those statements include statements regarding the intent, belief or current expectations of Anebulo Pharmaceuticals and members of its management, as well as the assumptions on which such statements are based. Prospective investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, including risks attendant to developing, testing and commercializing the company’s product candidates, including funding of clinical trials, and those described in Anebulo Pharmaceutical’s 2021 annual report on Form 10-K filed with the SEC, and that actual results may differ materially from those contemplated by such forward-looking statements. Except as required by federal securities law, Anebulo Pharmaceuticals undertakes no obligation to update or revise forward-looking statements to reflect changed conditions.

### Anebulo Pharmaceuticals, Inc. Condensed Balance Sheet Data

|                                      | <b>June 30,</b> |             |
|--------------------------------------|-----------------|-------------|
|                                      | <b>2021</b>     | <b>2020</b> |
| Cash                                 | \$19,985,645    | \$3,024,980 |
| Total assets                         | 21,653,491      | 3,028,480   |
| Total liabilities                    | 241,633         | 223,865     |
| Series A convertible preferred stock | -               | 2,975,752   |
| Total stockholders’ equity (deficit) | 21,411,858      | (171,137)   |

### Anebulo Pharmaceuticals, Inc. Condensed Statements of Operations

|                            | <b>Three months ended<br/>June 30,</b> |             | <b>Year ended June 30,</b> |             |
|----------------------------|--|-------------|----------------------------|-------------|
|                            | <b>2021</b>                            | <b>2020</b> | <b>2021</b>                | <b>2020</b> |
| Research and development   | \$ 1,806,692                           | \$ 150,000  | \$ 2,269,998               | \$ 150,000  |
| General and administrative | 678,013                                | 23,351      | 1,343,755                  | 23,351      |
| Total operating expenses   | 2,484,705                              | 173,351     | 3,613,753                  | 173,351     |
| Loss from operations       | (2,484,705)                            | (173,351)   | (3,613,753)                | (173,351)   |
| Other (income) expenses    |  |             |                            |             |
| Interest income            | (1,020)                                | -           | (1,020)                    | -           |

|  |                |              |                |              |
|--|----------------|--------------|----------------|--------------|
| Interest expense   | -              | 1,286        | 11,767         | 1,286        |
| Fair value adjustments for milestone warrants                | 26,626,710     | -            | 26,626,710     | -            |
| Other  | 1,344          | -            | 1,344          | -            |
| Total other expenses, net                                    | 26,627,034     | 1,286        | 26,638,801     | 1,286        |
| Net loss   | \$(29,111,739) | \$ (174,637) | \$(30,252,554) | \$ (174,637) |
| Deemed dividends   | -              | -            | (8,208,393)    | -            |
| Net loss attributable to common stockholders                 | \$(29,111,739) | \$ (174,637) | \$(38,460,947) | \$ (174,637) |
| Weighted average common share outstanding, basic and diluted | 18,293,103     | 12,000,000   | 13,612,701     | 12,000,000   |
| Net loss per share, basic and diluted                        | \$ (1.59)      | \$ (0.01)    | \$ (2.83)      | \$ (0.01)    |

View source version on businesswire.com:

<https://www.businesswire.com/news/home/20210922005961/en/>

**Anebulo Pharmaceuticals, Inc.**

Rex Merchant  
Chief Financial Officer  
(512) 598-0931  
[IR@anebulo.com](mailto:IR@anebulo.com)

**LHA Investor Relations**

Yvonne Briggs  
(310) 691-7100  
[ybriggs@lhai.com](mailto:ybriggs@lhai.com)

Source: Anebulo Pharmaceuticals, Inc.